Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421083 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT00421083 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 180 participants.
The verdict
NCT00421083, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a study of the efficacy and safety of on-demand dosing of tadalafil or placebo administered for 12 weeks to men with erectile dysfunction caused by spinal cord injury.
Interventions
- DRUG tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421083
The ClinicalTrials.gov registry entry for NCT00421083 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tadalafil is the first listed.
NCT00421083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00421083 about?
NCT00421083 is a clinical study titled "Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury". This is a study of the efficacy and safety of on-demand dosing of tadalafil or placebo administered for 12 weeks to men with erectile dysfunction caused by spinal cord injury.
What is the current status of trial NCT00421083?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2004-09. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00421083?
The interventions under investigation include: tadalafil (DRUG).
Who is sponsoring clinical trial NCT00421083?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.